首页 神经分泌生物科学(usNBIX)-基本信息

神经分泌生物科学(usNBIX)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:96.42

最高价:96.92

成交量:601682.0

昨收价:95.0

最低价:94.56

最新价:96.58

行情图标
概要信息

中文名称:神经分泌生物科学


英文名称:Neurocrine Biosciences


行业:医疗


简介:Neurocrine Biosciences, Inc.通过该公司的新研发平台为有大量医疗需求的疾病,发现和开发创新的和改变生活的药品,侧重于神经和内分泌的基础疾病和失调


电话:1-858-6177600


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

神经分泌生物科学公司是一家神经科学公司,着重于开发新型治疗神经与内分泌相关的疾病的药物,例如失眠、忧虑、消沉、多发性硬化症、糖尿病和内分泌相关的疾病。Neurocrine Biosciences公司临床开发阶段产品包括: elagolix——处于治疗子宫内膜异位症的III期临床试验阶段,处于治疗子宫肌瘤的IIb期临床试验阶段; 促肾上腺皮质激素释放因子受体1拮抗剂(Corticotropin-Releasing Factor Receptor1 Antagonist),目前处于治疗先天性肾上腺增生和压力有关的疾病的I/II期临床试验阶段; 囊泡单胺转运2抑制剂(VMAT2,Vesicular Monoamine Transporter 2 Inhibitor)——处于治疗运动障碍的III期临床试验阶段;同时处于治疗抽动秽语综合征的I期临床试验阶段。Neurocrine Biosciences公司研发阶段产品包括: VMAT2,用于治疗运动障碍、躁狂抑郁症和精神分裂症; 促性腺激素释放激素(GnRH)拮抗剂,对男性和女性的健康以及肿瘤学领域; 抗癫痫药物,用于治疗癫痫、原发性震颤、疼痛等; G蛋白偶联受体。此外,Neurocrine Biosciences公司还开发药物产品,用于治疗迟发性运动障碍,以及其它神经和内分泌有关的疾病和病症。Neurocrine Biosciences目前还与艾伯维公司(AbbVie Inc.)合作开发elagolix 和 GnRH产品,与Dainippon Sumitomo Pharma Co. Ltd.在日本合作开发indiplon(美国与辉瑞公司合作)。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-14 Benevich (Eric S.) Officer Sell 5835 87.44
2019-07-14 Bozigian (Haig P) Officer Buy 30680 32.99
2019-07-14 Bozigian (Haig P) Officer Sell 30680 87.50
2019-07-10 Bozigian (Haig P) Officer Sell 100 87.59
2019-07-10 Bozigian (Haig P) Officer Buy 100 32.99
2019-07-09 Bozigian (Haig P) Officer Buy 7120 32.99
2019-07-09 Bozigian (Haig P) Officer Sell 7120 87.63
2019-06-17 Bozigian (Haig P) Officer Buy 2100 32.99
2019-06-17 Bozigian (Haig P) Officer Sell 2100 87.82
2019-06-12 Bozigian (Haig P) Officer Buy 1432 32.99
2019-06-12 Bozigian (Haig P) Officer Buy 15836 19.59
2019-06-12 Bozigian (Haig P) Officer Sell 15836 82.56
2019-06-12 Bozigian (Haig P) Officer Sell 1432 83.29
2019-06-02 Bozigian (Haig P) Officer Buy 3435 19.59
2019-06-02 Bozigian (Haig P) Officer Sell 3435 85.51
2019-05-30 Bozigian (Haig P) Officer Sell 19297 85.02
2019-05-30 Bozigian (Haig P) Officer Buy 19297 19.59
2019-05-23 Bozigian (Haig P) Officer Sell 17486 80.03
2019-05-23 Bozigian (Haig P) Officer Buy 17486 19.59
2019-05-21 Bozigian (Haig P) Officer Sell 1300 80.03
2019-05-21 Bozigian (Haig P) Officer Buy 1300 19.59
2019-05-15 Bozigian (Haig P) Officer Sell 22439 80.13
2019-05-15 Bozigian (Haig P) Officer Buy 22439 35.99
2019-05-15 Bozigian (Haig P) Officer Sell 34376 80.13
2019-05-15 Bozigian (Haig P) Officer Sell 731 80.13

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Orbimed Advisors, LLC 1833200 2.01% 1339000 270.94% 2019-03-31
Fidelity Management & Research Company 4487154 4.90% -714802 -13.74% 2019-07-31
BlackRock Inc 5495336 6.02% 516419 10.37% 2019-03-31
Capital Research and Management Company 5653200 6.17% 1204600 27.08% 2019-07-31
Vanguard Group Inc 8155857 8.93% 76039 0.94% 2019-03-31
Janus Capital Management LLC 8361282 9.13% 493615 6.27% 2019-07-31
HHG PLC 8811961 9.65% 4547 0.05% 2019-03-31
Fidelity Management and Research Company 9053989 9.92% -2516225 -21.75% 2019-03-31
FMR Inc 10437053 11.43% -2579538 -19.82% 2019-03-31
Capital Research & Mgmt Co - Division 3 4426600 4.85% 901600 25.58% 2019-03-31
Fidelity SelectCo, LLC 3853799 4.21% 38580 1.01% 2019-07-31
Perceptive Advisors LLC 3758662 4.12% -849892 -18.44% 2019-03-31
State Street Corporation 2018154 2.21% 177309 9.63% 2019-03-31
Franklin Advisers, Inc. 2039138 2.23% 14200 0.70% 2019-03-31
Franklin Resources Inc 2039138 2.23% 14200 0.70% 2019-03-31
BlackRock Fund Advisors 2047586 2.24% 9125 0.45% 2019-07-31
Vanguard Investments Australia Ltd 2532855 2.77% 332 0.01% 2019-07-31
BB Biotech AG 3366786 3.69% 23696 0.71% 2019-03-31
T. Rowe Price Associates, Inc. 3476150 3.81% -533213 -13.30% 2019-03-31
Bellevue Asset Management AG 3507644 3.83% 106708 3.14% 2019-07-31
Amvescap Plc. 2128862 2.33% -4180 -0.20% 2018-12-31
Deutsche Asset Management Investment GmbH 3158974 3.46% 2397167 314.67% 2019-05-31
Artisan Partners Limited Partnership 1672187 1.84% -165077 -8.98% 2018-12-31
Fidelity Institutional Asset Management 1435253 1.58% -31949 -2.18% 2018-09-30
Invesco Advisers, Inc 1908941 2.11% -285534 -13.01% 2018-06-30
BlackRock Institutional Trust Company NA 2395891 2.64% -47509 -1.94% 2018-06-30
Wellington Management Company LLP 2405500 2.65% 33827 1.43% 2018-06-30
Franklin Advisers Inc 1825386 2.02% -531200 -22.54% 2018-06-30
State Street Corp 1774067 1.96% -149001 -7.75% 2018-06-30
TimesSquare Capital Management, LLC 1481612 1.64% -318450 -17.69% 2018-06-30
AllianceBernstein LP 1164900 1.29% -82597 -6.62% 2018-06-30
Wells Capital Management Inc. 1009144 1.12% 103368 11.41% 2018-06-30
First Trust Advisors L.P. 979671 1.08% 52200 5.63% 2018-06-30
Baker Bros Advisors LP 944624 1.04% -- -- 2018-06-30
Point72 Asset Management, L.P. 895900 0.99% 820900 1094.53% 2018-06-30
Pictet Asset Management SA 939871 1.05% -180790 -16.13% 2018-03-31
Goldman, Sachs & Co. 921517 1.03% -325185 -26.08% 2018-03-31
Healthcor Management LP 1525000 1.72% -562110 -26.93% 2017-12-31
Goldman Sachs Asset Management LP 1005549 1.14% -118535 -10.55% 2017-09-30
Arrowpoint Asset Management, LLC 887946 1.00% -7633 -0.85% 2017-09-30
Capital World Investors 1481000 1.70% -- -- 2016-09-30
Westfield Capital Management Company, LP 1255995 1.45% -19580 -1.53% 2016-09-30
Senator Investment Group LP 1150000 1.32% 300000 35.29% 2016-09-30
Citadel Advisors Llc 1037519 1.19% 103974 11.14% 2016-09-30
OppenheimerFunds Inc 1002548 1.15% 170680 20.52% 2016-09-30
BlackRock Advisors LLC 943190 1.09% -17066 -1.78% 2016-09-30
Eagle Asset Management, Inc. 914500 1.05% -27153 -2.88% 2016-09-30
BlackRock, Inc. 6347260 3.00% 259983770 0.10% 1999-11-30
FMR LLC 11400773 3.00% 466975662 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity Advisor 726352 0.79% 55200 8.22% 2019-06-30
American Funds Growth Fund of Amer 3890500 4.25% 1002500 34.71% 2019-06-30
Vanguard Total Stock Market Index Fund 2512304 2.74% 451 0.02% 2019-06-30
Vanguard Small Cap Index 2333511 2.55% -36341 -1.53% 2019-06-30
Janus Henderson Enterprise Fund 1826798 1.99% -- -- 2019-06-30
Janus Mid Cap Growth Tr 1826798 1.99% -- -- 2019-06-30
Vanguard Small Cap Growth Index Fund 1337641 1.46% -6974 -0.52% 2019-06-30
T. Rowe Price Health Sciences Fund 1332018 1.45% -71800 -5.11% 2019-06-30
Vanguard Extended Market Index Fund 1256107 1.37% -2430 -0.19% 2019-06-30
Janus Henderson Research Fund 1185766 1.29% -92602 -7.24% 2019-06-30
First Trust NYSE Arca Biotech Fund 1106202 1.21% -2666 -0.24% 2019-07-31
Janus Henderson Triton Fund 1032834 1.13% -- -- 2019-06-30
Janus Henderson Global Life Sciences Fd 1018139 1.11% -14824 -1.44% 2019-06-30
American Funds Fundamental Invs 1009400 1.10% 93200 10.17% 2019-06-30
T. Rowe Price New Horizons Fund 928685 1.01% -3000 -0.32% 2019-06-30
iShares Nasdaq Biotechnology ETF 901144 0.98% 9383 1.05% 2019-07-30
Fidelity 743400 0.81% -- -- 2019-06-30
SPDR 700767 0.77% -5560 -0.79% 2019-06-28
DWS Verm 1680000 1.84% 1260000 300.00% 2019-04-30
Vanguard Small Cap Index Fund 2372517 2.60% 15166 0.64% 2019-04-30
VA CollegeAmerica The Gr Fd of Amer 2738000 3.01% 2738000 -- 2018-12-31
Artisan Mid Cap Fund 674514 0.74% -- -- 2018-10-31
Franklin Biotechnology Discovery Fund 649305 0.72% 151300 30.38% 2018-11-30
iShares Nasdaq Biotechnology 1019947 1.12% -1941 -0.19% 2018-09-12
Artisan Mid Cap Investor 732194 0.81% -67299 -8.42% 2018-06-30
Janus Global Life Sciences D 787513 0.87% -68721 -8.03% 2018-06-30
T. Rowe Price Health Sciences 2350166 2.60% -35742 -1.50% 2018-06-30
Vanguard Total Stock Mkt Idx 2255500 2.49% 2346 0.10% 2018-07-31
Janus Enterprise D 1825633 2.02% -- -- 2018-06-30
T. Rowe Price New Horizons 1788746 1.98% -157063 -8.07% 2018-06-30
Vanguard Small Cap Growth Index Inv 1291418 1.43% 18334 1.44% 2018-07-31
Vanguard Extended Market Idx Inv 1191667 1.32% -- -- 2018-07-31
Hartford MidCap A 1187436 1.31% -133846 -10.13% 2018-07-31
Janus Research D 1140748 1.26% -- -- 2018-06-30
Janus Triton D 889607 0.98% -- -- 2018-06-30
First Trust NYSE Arca Biotech ETF 718040 0.78% -- -- 2018-09-13
VA CollegeAmerica Smcap World 529E 658000 0.73% -30000 -4.36% 2018-06-30
Delaware Smid Cap Growth A 597225 0.66% 26125 4.57% 2018-05-31
Invesco Mid Cap Growth A 645904 0.72% -132041 -16.97% 2018-03-31
Invesco Mid Cap Growth 645904 0.72% 635644 6195.36% 2018-03-31
Franklin Biotechnology Discovery A 740100 0.83% -158300 -17.62% 2017-12-31
T. Rowe Price Mid-Cap Growth 850000 0.98% 850000 -- 2016-09-30
Fidelity® Contrafund® Fund 2136614 2.50% 325855 18.00% 2015-09-30
iShares Russell 2000 (AU) 1352605 1.70% -1704 -0.10% 2015-11-19
Fidelity® Select Health Care Portfolio 1100000 1.30% -- -- 2015-09-30
Fidelity® OTC Portfolio 984200 1.10% 345747 54.10% 2015-09-30
VA CollegeAmerica Small Cap World 927500 1.10% -170200 -15.50% 2015-09-30
Janus Global Life Sciences Fund 898044 1.10% -121463 -11.90% 2015-09-30
Fidelity® Select Biotechnology Portfolio 3582851 4.20% -- -- 2015-09-30

Stephen A. Sherwin Stephen A. Sherwin founded Abgenix, Inc. and Ceregene, Inc. Dr. Sherwin is Member of American Society of Clinical Oncology, Member of American Association for Cancer Research, Venture Partner at Third Rock Ventures LLC, Professor at the University of California and Clinical Professor at The University of California, San Francisco and on the board of 6 other companies. He previously was Chairman & Chief Executive Officer of Cell Genesys, Inc., Chairman at Abgenix, Inc., Chairman of Ceregene, Inc., Vice President-Clinical Research at Genentech, Inc., Director at Biogen Idec New Ventures, Inc., Chairman-Emeritus at Biotechnology Innovation Organization and Principal at National Cancer Institute. He received an undergraduate degree from Yale University and a doctorate from Harvard Medical School.
George J. Morrow George J. Morrow is on the board of Vical, Inc., Neurocrine Biosciences, Inc. and Align Technology, Inc. Mr. Morrow previously occupied the position of Executive VP-Global Commercial Operations at Amgen, Inc., Vice President-Marketing of Merck & Co., Inc. and President, Chief Executive Officer & Director at Glaxo Wellcome, Inc. He received a graduate degree from Bryn Mawr College, an MBA from The Fuqua School of Business, an undergraduate degree from Southampton City College, an MBA from Duke University and an undergraduate degree from Long Island University.
Kevin Charles Gorman Kevin Charles Gorman founded Neurocrine Biosciences, Inc. Currently, Dr. Gorman is Chief Executive Officer & Director at this company. He is also on the board of Xencor, Inc. In the past Dr. Gorman held the position of Principal at Avalon Medical Partners LP. Dr. Gorman received a doctorate and an MBA from the University of California, Los Angeles.
Richard F. Pops Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University.
Timothy P. Coughlin Presently, Timothy P. Coughlin is Vice President of Neurocrine Biosciences, Inc. Mr. Coughlin is also on the board of aTyr Pharma, Inc., Peloton Therapeutics, Inc., Fate Therapeutics, Inc. and Retrophin, Inc. In the past Mr. Coughlin held the position of Vice President-Financial Services at California Healthcare Institute and Senior Manager-Health Sciences Practice at Ernst & Young LLP. Mr. Coughlin received an undergraduate degree from Temple University (Pennsylvania) and a graduate degree from San Diego State University.
Darin M. Lippoldt Currently, Darin M. Lippoldt is Secretary & Chief Legal Officer of Neurocrine Biosciences, Inc. He previously held the position of Associate General Counsel at Amylin Pharmaceuticals, Inc. and Secretary, Chief Compliance Officer & Executive VP at Volcano Corp. He received an undergraduate degree and a graduate degree from St. Mary's University.
William H. Rastetter Founder of Receptos LLC and Apoptos, Inc., William H. Rastetter is a businessperson who has been at the head of 11 different companies and presently is Chairman at Fate Therapeutics, Inc., Chairman for Neurocrine Biosciences, Inc. and Advisor at IIF Management Co. LLC. Dr. Rastetter is also on the board of 5 other companies. In the past Dr. Rastetter occupied the position of Chairman of Celgene Corp. Executive Chairman for Receptos LLC and Chairman & Chief Executive Officer of Apoptos, Inc. (both are subsidiaries of Celgene Corp.), Executive Chairman for Biogen, Inc. and Chairman & Chief Executive Officer at IDEC Pharmaceuticals Corp. (a subsidiary of Biogen, Inc.), Chairman of Illumina, Inc., Partner at Venrock Associates, Chairman of Cerulean Pharma, Inc., Director-Corporate Ventures at Genentech, Inc., Associate Professor at Massachusetts Institute of Technology and Faculty Member at Harvard University. William H. Rastetter received a doctorate and a graduate degree from Harvard University and an undergraduate degree from Massachusetts Institute of Technology.
Richard F. Pops Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University.
Richard F. Pops Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University.
Gary A. Lyons Founder of GL Biomed, Gary A. Lyons is a businessperson who has been at the head of 5 different companies and presently is Chairman for Retrophin, Inc., Chairman at Rigel Pharmaceuticals, Inc. and President of GL Biomed. Mr. Lyons is also on the board of Vical, Inc., Neurocrine Biosciences, Inc. (former President, Chief Executive Officer & Director) and Novus Therapeutics, Inc. In his past career Mr. Lyons was Executive Chairman of NeurogesX, Inc., Sales Director-American Critical Care at American Hospital Supply Corp. and Vice President-Business Development & Sales at Genentech, Inc. Mr. Lyons received an undergraduate degree from the University of New Hampshire and an MBA from Kellogg School of Management.
Julie Cooke Currently, Julie Cooke is Chief Human Resources Officer at Neurocrine Biosciences, Inc. In her past career she occupied the position of Compensation Director at Pepsi-Cola North America, Director-Human Resources for Gateway Computers, Vice President-Human Resources for Life Technologies Corp., Vice President-Human Resources for SGX Pharmaceuticals, Inc. and Senior Vice President-Human Resources of Sanford Burnham Prebys Medical Discovery Institute. Ms. Cooke received an undergraduate degree from Colorado College.
Haig P. Bozigian Haig P. Bozigian is Chief Development Officer for Neurocrine Biosciences, Inc. Dr. Bozigian previously was Associate Director-Pharmacokinetics at Sphinx Pharmaceuticals Corp and Director-Pharmaceutical Development at ProCyte Corp. Haig P. Bozigian received an undergraduate degree from the University of Massachusetts, a doctorate from the University of Arizona and a graduate degree from the University of Nebraska Medical Center.
Dimitri E. Grigoriadis Presently, Dimitri E. Grigoriadis holds the position of Chief Research Officer at Neurocrine Biosciences, Inc. Dr. Grigoriadis is also Member of International Society of Psychoneuroendocrinology. Dr. Grigoriadis previously occupied the position of Senior Scientist-Neuroscience Group at DuPont Pharmaceuticals Co. Dr. Grigoriadis received an undergraduate degree from the University of Guelph and a doctorate and a graduate degree from the University of Toronto.
Bill Wilson Presently, Bill Wilson holds the position of Vice President-Information Technology & Operations at Neurocrine Biosciences, Inc. Mr. Wilson is also Founding Member at CIO Executive Council.
Eric S. Benevich Eric S. Benevich is Chief Commercial Officer at Neurocrine Biosciences, Inc. Mr. Benevich previously occupied the position of Senior Director-Marketing at Peninsula Pharmaceuticals, Inc. and Vice President-Communications & Marketing at Avanir Pharmaceuticals, Inc. Eric S. Benevich received an undergraduate degree from Washington State University.
Malcolm Lloyd-Smith Presently, Malcolm Lloyd-Smith is Chief Regulatory Officer at Neurocrine Biosciences, Inc. He previously occupied the position of Vice President-Worldwide Regulatory Affairs at DuPont Pharmaceuticals Co., Director-International Regulatory Affairs at DuPont Merck Pharmaceutical Co., Senior VP-Regulatory Affairs, Quality & Clinical at Mallinckrodt Hospital Products, Inc., Manager-Regulatory Affairs & Quality Assurance at DuPont de Nemours International SARL and Vice President & Head-Global Regulatory Affairs at Elan Pharmaceuticals, Inc. Malcolm Lloyd-Smith received an undergraduate degree from the University of Leeds and a graduate degree from the University of Hertfordshire.
Bill Wilson Presently, Bill Wilson holds the position of Vice President-Information Technology & Operations at Neurocrine Biosciences, Inc. Mr. Wilson is also Founding Member at CIO Executive Council.
Gary A. Lyons Gary A. Lyons is a businessperson who founded GL Biomed and who has been at the helm of 5 different companies. Currently, Mr. Lyons occupies the position of Chairman for Retrophin, Inc., Chairman of Rigel Pharmaceuticals, Inc. and President at GL Biomed. He is also on the board of Vical, Inc., Neurocrine Biosciences, Inc. (former Chief Executive Officer), Cytori Therapeutics, Inc. and Novus Therapeutics, Inc. In the past he was Executive Chairman for NeurogesX, Inc., Sales Director-American Critical Care at American Hospital Supply Corp. and Vice President-Business Development & Sales at Genentech, Inc. Gary A. Lyons received an undergraduate degree from the University of New Hampshire and an MBA from Kellogg School of Management.
Alfred W. Sandrock Presently, Alfred W. Sandrock occupies the position of Chief Medical Officer & Executive Vice President at Biogen, Inc. and Chief Medical Officer of Biogen Idec, Inc. (North Carolina) (a subsidiary of Biogen, Inc.). Dr. Sandrock is also on the board of Neurocrine Biosciences, Inc. and Disarm Therapeutics, Inc. and Professor at Harvard Medical School and Member of American Academy of Neurology. Dr. Sandrock received a doctorate from Harvard Medical School, a doctorate from Harvard University and an undergraduate degree from Stanford University.
George J. Morrow George J. Morrow is on the board of Vical, Inc., Neurocrine Biosciences, Inc. and Align Technology, Inc. Mr. Morrow previously occupied the position of Executive VP-Global Commercial Operations at Amgen, Inc., Vice President-Marketing of Merck & Co., Inc. and President, Chief Executive Officer & Director at Glaxo Wellcome, Inc. He received a graduate degree from Bryn Mawr College, an MBA from The Fuqua School of Business, an undergraduate degree from Southampton City College, an MBA from Duke University and an undergraduate degree from Long Island University.
Kyle Gano Kyle Gano is Chief Business Development Officer at Neurocrine Biosciences, Inc. He received an undergraduate degree from the University of Oregon, an undergraduate degree from the University of Washington and a doctorate and an MBA from the University of California, Los Angeles.
Matthew C. Abernethy Presently, Matthew C. Abernethy holds the position of Chief Financial Officer at Neurocrine Biosciences, Inc., Vice President-Finance for Biomet Orthopedics LLC and Treasurer of Biomet, Inc. Mr. Abernethy is also on the board of BIOCOM. He previously held the position of Vice President, Investor Relations & Treasurer at Zimmer Biomet Holdings, Inc. and Treasurer for Zimmer US, Inc. (a subsidiary of Zimmer Biomet Holdings, Inc.). He received an undergraduate degree from Grace College & Seminary and an MBA from The University of Chicago.
Eiry W. Roberts Eiry W. Roberts occupies the position of Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts previously held the position of Vice President-Autoimmune Product Development at Eli Lilly & Co.
Navjot Rai Currently, Navjot Rai occupies the position of Investor Relations Contact at Neurocrine Biosciences, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐